*The Clinical Characteristics and Treatment Status of Psoriatic Arthritis DOI: http://dx.doi.org/10.5772/intechopen.102077*


#### **Table 4.**

*The distribution pattern of the peripheral lesions.*


#### **Table 5.**

*The distribution pattern of enthesitis.*


*Fisher's direct exact test was performed for each patient for obesity and concomitant diseases. BMI, body mass index.*

#### **Table 6.**

*The incidence of obesity, hypertension, and diabetes mellitus in patients with psoriatic arthritis and comparison with a Japanese cohort.*

kidney disease (CKD) in 3 cases (4.7%). Diabetes mellitus was type 2 in all 12 cases. A statistically significant correlation was found between PsA and obesity (p < 0.0001). No statistically significant correlations were observed between PsA and hypertension (p = 0.43) or diabetes mellitus (p = 0.57) (**Table 6**).

**Table 7** shows the treatments the patients with PsA received. NSAIDs were prescribed in 25 cases (39%). Several csDMARDs were prescribed in 41 cases (64%), where 21 cases (32.8%) received methotrexate, 9 cases (14%) received salazosulfapyridine, and 3 cases (4.7%) received cyclosporine. Several bDMARDs were prescribed in 33 cases (51.5%), with the most prescribed bDMARDs being


*bDMARDs, biologic disease modifying antirheumatic drugs; csDMARDs, conventional synthetic disease modifying antirheumatic drugs; NSAIDs, nonsteroidal anti-inflammatory drugs.*

#### **Table 7.**

*The treatment status for psoriatic arthritis.*

adalimumab and infliximab, which were both prescribed in 10 cases (15.6%), followed by ixekizumab in 4 cases (6.3%), etanercept and sekukinumab both in 3 cases (4.7%), and certolizumab pegol, tocilizumab, and guselkumab each prescribed in 1 case (1.6%). Other treatments included prednisolone in a single case (1.6%) and apremilast, ascorbic acid, calcium pantothenate, and biotin, each prescribed in two cases (3.1%) (**Table 7**).
